Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02317874 | Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2023 | clinicaltrials |
| NCT04293094 | Study of AMG 650 in Adult Participants With Advanced Solid Tumors | completed | Phase 1 | 66 | Volastra Therapeutics, Inc.INDUSTRY | 7 | Aug 24, 2023 | clinicaltrials |
| NCT04116710 | A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors | completed | Phase 1 | 15 | Heat BiologicsINDUSTRY | 1 | Aug 23, 2023 | clinicaltrials |
| NCT03834948 | AO-176 in Multiple Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 57 | Arch OncologyINDUSTRY | 1 | Aug 22, 2023 | clinicaltrials |
| NCT02959619 | Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK | completed | Phase 1 | 48 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03990454 | Safety Study of SLC-391 in Subjects With Solid Tumors | completed | Phase 1 | 35 | SignalChem Lifesciences CorporationINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05119998 | A Phase I Study of IBI325 in Patients With Advanced Solid Tumor | completed | Phase 1 | 48 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04697524 | Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer | completed | N/A | 30 | University of California, San FranciscoOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT02277717 | First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients | completed | Phase 1 | 185 | Byondis B.V.INDUSTRY | 4 | Aug 14, 2023 | clinicaltrials |
| NCT04601402 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | completed | Phase 1 | 11 | Genome & CompanyINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT00084734 | Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 61 | Roswell Park Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00107250 | AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07) | completed | Phase 1 | 50 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00357747 | AEG35156 and Docetaxel in Treating Patients With Solid Tumors | completed | Phase 1 | 10 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00372736 | AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors | completed | Phase 1 | 27 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00390117 | AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | 34 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00443976 | Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 35 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00471432 | OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | completed | Phase 1 | 40 | NCIC Clinical Trials GroupNETWORK | 0 | Aug 4, 2023 | clinicaltrials |
| NCT00504296 | SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 39 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01184274 | A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia | completed | Phase 1 | 12 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02343718 | Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours | completed | Phase 1 | 7 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04047589 | Assessing Exercise Behavior and Preferences Among Patients and Oncologists | completed | — | 60 | Indiana UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT00813423 | Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2023 | clinicaltrials |
| NCT02506517 | A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene | completed | Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03745989 | Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) | completed | Phase 1 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Jul 27, 2023 | clinicaltrials |
| NCT04456140 | Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study | completed | Phase 1 | 230 | Mayo ClinicOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT02847130 | Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology | completed | — | 530 | Children's Oncology GroupNETWORK | 2 | Jul 19, 2023 | clinicaltrials |
| NCT02503774 | MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors. | completed | Phase 1 | 192 | MedImmune LLCINDUSTRY | 3 | Jul 11, 2023 | clinicaltrials |
| NCT03718091 | M6620 (VX-970) in Selected Solid Tumors | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT04695847 | M1231 in Participants With Solid Tumors | completed | Phase 1 | 23 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | Jul 7, 2023 | clinicaltrials |
| NCT00091169 | Levocarnitine in Treating Fatigue in Cancer Patients | completed | Phase 3 | 376 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02610075 | Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | completed | Phase 1 | 62 | AstraZenecaINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05116891 | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Cantargia ABINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT04337203 | Shared Healthcare Actions and Reflections Electronic Systems in Survivorship | completed | N/A | 40 | Wake Forest University Health SciencesOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03989115 | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC | completed | Phase 1 / Phase 2 | 113 | Revolution Medicines, Inc.INDUSTRY | 2 | Jun 26, 2023 | clinicaltrials |
| NCT01525394 | A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval | completed | Phase 1 | 52 | Eisai Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02797977 | A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects | completed | Phase 1 / Phase 2 | 153 | Sierra Oncology LLC - a GSK companyINDUSTRY | 2 | Jun 22, 2023 | clinicaltrials |
| NCT04914117 | A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours | completed | Phase 1 | 7 | RemeGen Co., Ltd.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003266 | Methylphenidate in Treating Patients With Melanoma | completed | Phase 3 | 200 | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 18, 2023 | clinicaltrials |
| NCT00002520 | Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer | completed | N/A | 434 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04122625 | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143(SMARTPLUS-106) | completed | Phase 1 / Phase 2 | 46 | Debiopharm International SAINDUSTRY | 3 | Jun 12, 2023 | clinicaltrials |
| NCT05898451 | Effect of Refnot on Immunity in Cancer Patients(R-2) | completed | Phase 2 | 55 | Refnot-Pharm LtdINDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT02986100 | Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib(AME) | completed | Phase 1 | 6 | pharmaand GmbHINDUSTRY | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03499444 | A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor | completed | Phase 1 | 29 | pharmaand GmbHINDUSTRY | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03733951 | KN046 in Subjects With Advanced Solid Tumors and Lymphoma | completed | Phase 1 | 139 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jun 9, 2023 | clinicaltrials |
| NCT04902144 | Clinical Outcomes for Offering Genetic Testing in a Tiered Approach | completed | N/A | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 9, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Aug 29, 2023source: clinicaltrials